Inhibitors of CXCR2

Patent metadata

Field	Value
Publication number	US-11040960-B2
Application number	US-201916438880-A
Country	US
Kind code	B2
Filing date	Jun 12, 2019
Priority date	Nov 19, 2015
Publication date	Jun 22, 2021
Grant date	Jun 22, 2021

Abstract

Compounds are provided as inhibitors of CXCR2, having the structure:

First claim

What is claimed is:

1. A pharmaceutical composition comprising a compound having formula (Ia),

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient,
wherein
R 1 is selected from the group consisting of Cl and CH 3 ;
R 3b is selected from the group consisting of H and D;
R 4 is a member selected from the group consisting of H and C 1-8 alkyl, wherein the C 1-8 alkyl is optionally substituted with —CONR a R b , —OC(O)NR b , —NR a C(O)R b , —NR a C(O) 2 R c , —NR a R b , and —OR a , wherein each R a and R b is independently selected from hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl, and R c is selected from C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl;
R 5a and R 5b are each members independently selected from the group consisting of H, F, Cl and CH 3 ;
R 6a and R 6b are each members independently selected from the group consisting of H, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl; or optionally R 6a and R 6b are taken together to form oxo (═O);
or any salts, solvates, hydrates, N-oxides or rotamers thereof.

2. The pharmaceutical composition of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3b is H; R 4 is H or CH 3 ; R 5a is H, F or Cl; R 5b is H, F, Cl; R 6a and R 6b are independently selected from the group consisting of H and CH 3 , or are taken together to form oxo (═O).

3. The pharmaceutical composition of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3b is D; R 4 is H or CH 3 ; R 5a is H, F or Cl; R 5b is H, F, Cl; R 6a and R 6b are independently selected from the group consisting of H and CH 3 , or are taken together to form oxo (═O).

4. The pharmaceutical composition of claim 1 further comprising one or more additional therapeutic agents.

5. The pharmaceutical composition of claim 4 , wherein the one or more additional therapeutic agents are selected from the group consisting of: drugs that block the activity of CTLA-4 (CD152), PD-1 (CD279), PDL-1 (CD274), TIM-3, LAG-3 (CD223), VISTA, KIR, NKG2A, BTLA, PD-1H, TIGIT, CD96, 4-1BB (CD137), 4-1BBL (CD137L), GARP, CSF-1R, A2AR, CD73, CD47, tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3 dioxygenase (IDO), and agonists of OX40, GITR, 4-1BB, ICOS, STING or CD40.

6. A method of treating a disease or disorder selected from the group consisting of psoriasis, rheumatoid arthritis, radiation induced fibrotic lung disease, autoimmune bullous dermatosis (AIBD), chronic obstructive pulmonary disease, and ozone-induced airway inflammation in a subject in need thereof, said method comprising administering an effective amount of a pharmaceutical composition of claim 1 to said subject.

7. A method of treating a cancer selected from the group consisting of rhabdomyocarcoma, Lewis lung carcinoma (LLC), non-small cell lung cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, renal cell carcinoma (RCC), colorectal cancer (CRC), acute myeloid leukemia (AML), breast cancer, gastric cancer, prostatic small cell neuroendocrine carcinoma (SCNC), liver cancer, glioblastoma, liver cancer, oral squamous cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, thyroid papillary cancer, intrahepatic cholangiocellular carcinoma, hepatocellular carcinoma, bone cancer, and nasopharyngeal carcinoma in a subject in need thereof, said method comprising administering an effective amount of a pharmaceutical composition of claim to said subject.

8. A method of claim 7 , wherein the pharmaceutical composition, is used to treat cancer alone or in combination with one or more other anti-cancer therapies.

9. A method of claim 8 , wherein the pharmaceutical composition, is used to treat cancer in combination with one or more of a cytotoxic chemotherapy, an anti-cancer vaccine therapy, an anti-tumor vaccine therapy, an anti-immunocytokine therapy, an immunocytokine therapy, a chimeric antigen receptor (CAR) T cell therapy, or a gene transfer therapy.

10. A method of claim 8 , wherein the pharmaceutical s composition, is used to treat cancer in combination with one or more checkpoint inhibitor therapies.

11. The method of claim 8 wherein the one or more other anti-cancer therapy is selected from the group consisting of: drugs that block the activity of CTLA-4 (CD152), PD-1 (CD279), PDL-1 (CD274), TIM-3, LAG-3 (CD223), VISTA, KIR, NKG2A, BTLA, PD-1H, TIGIT, CD96, 4-1BB (CD137), 4-1BBL (CD137L), GARP, CSF-1R, A2AR, CD73, CD47, tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3 dioxygenase (IDO), and agonists of OX40, GITR, 4-1BB, ICOS, STING or CD40.

12. The pharmaceutical composition of claim 1 , wherein the compound of formula (Ia) is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 1 , wherein the compound of formula (Ia) is selected from the group consisting of

14. The pharmaceutical composition of claim 1 , wherein the compound of formula (Ia) is selected from the group consisting of

Assignees

• Chemocentryx Inc

Inventors

• Chen Xi
• Dragoli Dean R
• Fan Junfa
• Kalisiak Jaroslaw
• Leleti Manmohan Reddy
• Malathong Viengkham
• Mcmahon Jeffrey
• Tanaka Hiroko
• Yang Ju
• Yu Chao
• Zhang Penglie
• Mali Venkat

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D405/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• C07B59/002

  Heterocyclic compounds · CPC title